Pricing Log in Create free account

Intellia Therapeutics, Inc. (NTLA) vs Nuvation Bio Inc. (NUVB)

Intellia Therapeutics, Inc. and Nuvation Bio Inc. are both Biotechnology companies. Intellia Therapeutics, Inc. and Nuvation Bio Inc. are of similar size ($1.7B and $1.6B). Nuvation Bio Inc. grew revenue faster over the last twelve months: 1,083.6% against 12.6%. Nuvation Bio Inc. has the higher net margin (−88.2% vs −672.2%) and the higher return on invested capital (0.00% vs −91.3%). Across the 17 metrics below, Nuvation Bio Inc. leads on 13 and Intellia Therapeutics, Inc. on 4.

Valuation

Metric NTLA NUVB Biotechnology median
P/E n/m n/m 8.50
P/S 25.62 9.13 9.71
P/B 2.09 6.11 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 18.26 6.71 9.21
Earnings yield (29.42%) (9.76%) (33.15%)
Free cash flow yield (22.87%) (7.79%) (25.50%)

Profitability

Metric NTLA NUVB Biotechnology median
Gross margin 100.00% 88.18% 65.16%
Operating margin (711.66%) (81.00%) 0.00%
Net margin (672.16%) (88.19%) 0.00%
Free cash flow margin (585.82%) (71.17%) 0.00%
Return on equity (55.44%) (47.81%) (56.36%)
Return on assets (45.55%) (21.53%) (48.04%)
Return on invested capital (91.28%) 0.00% 0.00%

Growth

Metric NTLA NUVB Biotechnology median
Revenue growth (TTM) 12.58% 1,083.56% 6.02%
EPS growth (last fiscal year) 27.43% 71.56% 30.26%
Revenue growth, 5-year CAGR 3.13% — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric NTLA NUVB Biotechnology median
Debt to equity 0.00 0.98 0.00
Current ratio 6.65 8.37 4.72
Net debt to EBITDA 1.06 2.26 0.96

Dividend

Metric NTLA NUVB Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric NTLA NUVB Biotechnology median
Market cap 1.59b 1.67b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack